Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias

被引:34
|
作者
Muayqil, Taim [1 ]
Camicioli, Richard [2 ]
机构
[1] King Saud Univ, Div Neurol, Riyadh, Saudi Arabia
[2] Univ Alberta, Div Neurol, Edmonton, AB, Canada
来源
关键词
Dementia; Alzheimer; Dementia therapy; Combination treatment; Cholinesterase inhibitors; Memantine; Side effects;
D O I
10.1159/000343479
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: N-methyl-D-aspartic acid antagonists (memantine) and cholinesterase inhibitors (ChEIs) are the only two approved classes of drugs to treat dementia; this paper explores the evidence for using these two treatments in combination. Objective: To determine the efficacy and safety of using combination therapy with memantine and a ChEI to treat dementia in comparison to monotherapy with either memantine or a ChEI. Methods: In March 2012, we systematically searched MEDLINE/PubMed, EMBASE, Cochrane library, and grey literature databases. All study types were included, except for case series or reports, which looked at combination therapy versus monotherapy in various dementing disorders. Data was pooled for blinded ran-domized controlled trials (RCTs) only; mean differences and standardized mean differences were used to determine effect sizes. Results: Thirteen studies were included in this review; 3 were blinded RCTs, with a total of 971 Alzheimer's disease (AD) patients, which were included into the meta-analysis. No papers were found that primarily addressed combination therapy in other dementias. In the meta-analysis, small but statistically significant effect sizes were seen in favor of combination therapy among patients with moderate to severe AD on the scales of cognition (0.45-0.52; p < 0.0001), scales of functional outcomes (0.23-0.3; p < 0.01), and the neuropsychiatric inventory (3.7-4.4; p < 0.0001). Among the open-label studies, 3 out of 6 suggested benefits, as did the 4 included cohort studies. However, the high risk of bias encountered in the latter two study designs limits deducing any conclusions about benefit. Conclusion: Although there were statistically significant changes in favor of combination therapy in moderate to severe AD, heterogeneity in scales and patient characteristics exists. However, it is unclear if clinically significant outcomes can be achieved using the combination therapy. More studies are required before a recommendation for combination therapy can be made. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:546 / 572
页数:27
相关论文
共 50 条
  • [21] Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
    Meng, Yan-Hong
    Wang, Pan-Pan
    Song, Ya-Xue
    Wang, Jian-Hua
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (03) : 1611 - 1624
  • [22] Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials
    Dou, Kai-Xin
    Tan, Meng-Shan
    Tan, Chen-Chen
    Cao, Xi-Peng
    Hou, Xiao-He
    Guo, Qi-Hao
    Tan, Lan
    Mok, Vincent
    Yu, Jin-Tai
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [23] Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
    Kai-Xin Dou
    Meng-Shan Tan
    Chen-Chen Tan
    Xi-Peng Cao
    Xiao-He Hou
    Qi-Hao Guo
    Lan Tan
    Vincent Mok
    Jin-Tai Yu
    [J]. Alzheimer's Research & Therapy, 10
  • [24] Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Sepehry, Amir A.
    Sarai, Michael
    Hsiung, Ging-Yuek R.
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2017, 44 (03) : 267 - 275
  • [25] A SYSTEMATIC REVIEW AND META-ANALYSIS OF 19 MEMANTINE RANDOMIZED CLINICAL TRIALS IN ALZHEIMER DISEASE
    Blanco, L.
    Capella, D.
    Castells, X.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 14 - 14
  • [26] Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
    Dominik, Glinz
    Viktoria, Gloy L.
    Andreas, Monsch U.
    Reto, Kressig W.
    Chandni, Patel
    Alba, McCord Kimberly
    Zanfina, Ademi
    Yuki, Tomonaga
    Matthias, Schwenkglenks
    Heiner, Bucher C.
    Heike, Raatz
    [J]. SWISS MEDICAL WEEKLY, 2019, 149
  • [27] Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis
    Gao, Yaqi
    Liu, Yulin
    Li, Yanfang
    [J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024,
  • [28] Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias
    Thomas, Stuart J.
    Grossberg, George T.
    [J]. CLINICAL INTERVENTIONS IN AGING, 2009, 4 : 367 - 377
  • [29] Efficacy of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis
    Kani, C.
    Papanikolaou, K.
    Pehlivanidis, A.
    Papadopoulou-Daifoti, Z.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S505 - S505
  • [30] Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Tan, Chen-Chen
    Yu, Jin-Tai
    Wang, Hui-Fu
    Tan, Meng-Shan
    Meng, Xiang-Fei
    Wang, Chong
    Jiang, Teng
    Zhu, Xi-Chen
    Tan, Lan
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 (02) : 615 - 631